Johnson & Johnson unit Scios reported two additional deaths occurred during a study of its heart failure drug Natrecor three years ago, but the company said the cases do not indicate increased risk from the drug. A total of seven patients died within 30 days of treatment with Natrecor. The company is preparing a report for the FDA due by April, and the authors of a report on the original study published in the October 2005 issue of the Journal of Emergency Medicine will update their report.

Full Story:
ABC News

Related Summaries